News
Huma aquires Alcedis to form clinical trials division
Published
11 months agoon


Health tech company Huma Therapeutics is to form an advanced clinical trials division following the acquisition of Alcedis GmbH.
The new division with offer digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralised trials.
Huma’s modular platforms are used by more than 3,000 hospitals and clinics, with more than 1.8 million active users 650,000+ participants.
The company helps the health service to provide ‘hospitals at home’.
Huma CEO and founder, Dan Vahdat, said:
“Huma has been a leader in digital-first care and research, partnering with health systems and pharma companies and now with this acquisition we’re set to redefine the clinical trials sector.”
Headquartered in Giessen, Germany, Alcedis has more than 25 years of clinical trial experience.
The clinical trials company coordinates studies from the initial concept to the delivery of final results.
Alcedis managing director, Hanno Härtlein, said:
“We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma’s award-winning technology-platform.
“Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects.”
Jeanne Kehren, Senior Vice President, Digital & Commercial Innovation & Chief Information Officer, Bayer AG, added:
“The combined company will offer a one-stop shop for remote access, data, logistics and execution with advanced digital technology shaping a new clinical research ecosystem.”
60
SHARES
You may like


Microsoft invests £2.5 billion in UK AI


TMS shows promise in tackling depression ‘epidemic’


AI depression app set for NHS clinical trial


UK Biobank releases world’s largest single set of sequencing data


Listen: Longevity, Eastern wisdom and Western science


Fundamental principles of healthcare digital twins


Tackling the diagnostic testing sustainability problem


Gym-going men ‘unaware’ of protein risk to fertility


Anti-choke mug protects Parkinson’s patients


AI model predicts breast cancer risk without racial bias
Sign up for free updates from Health Tech World
Trending stories
- Opinion4 weeks ago
We need to think differently about EPR deployments and redefine the pre-implementation approach
- News2 weeks ago
Choosing the right stem cell treatment centre
- Medtech2 days ago
TMS shows promise in tackling depression ‘epidemic’
- Research3 weeks ago
AI algorithm developed to measure muscle development